AKBA
Akebia Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.92
+2.26%Next report
Analyst consensus
- Next report date
- Nov 9, 2026
- EPS estimate
- -$0.03
- Revenue estimate
- $46.9M
Latest reported
- Last report date
- Aug 5, 2026
- EPS actual
- -$0.02
- EPS estimate
- -$0.04
- Revenue actual
- $49.1M
- Revenue estimate
- $48.9M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 6
- EPS misses (12Q)
- 5
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- -24.2%
- Revenue beats (12Q)
- 7
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $3.88
- PT range
- $1.00 – $6.00
- Analysts
- 4
3 Buy1 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 5, 2026 | -$0.04 | -$0.02 | Beat 52.38% | $49.1M |
| May 7, 2026 | -$0.01 | -$0.03 | Miss -200.00% | $53.5M |
| Feb 26, 2026 | -$0.03 | -$0.05 | Miss -53.80% | $57.6M |
| Aug 7, 2025 | -$0.02 | $0.00 | Beat 104.55% | $62.5M |
| May 8, 2025 | -$0.03 | $0.03 | Beat 200.00% | $57.3M |
| Mar 13, 2025 | -$0.05 | -$0.10 | Miss -100.00% | $46.5M |
| Nov 7, 2024 | -$0.05 | -$0.10 | Miss -100.00% | $37.4M |
| Aug 8, 2024 | -$0.06 | -$0.04 | Beat 33.33% | $43.6M |
| May 9, 2024 | -$0.09 | -$0.09 | In line | $32.6M |
| Mar 14, 2024 | $0.00 | $0.00 | Beat 100.00% | $56.2M |
| Aug 25, 2023 | -$0.03 | -$0.06 | Miss -140.00% | $56.4M |
| Mar 9, 2023 | -$0.14 | -$0.04 | Beat 71.43% | $55.2M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 9, 2026